Paul Meyvisch
Overview
Explore the profile of Paul Meyvisch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cougnaud L, Faes M, Van Krunckelsven D, De Roeck A, Pasetto M, Fieuw A, et al.
Front Med (Lausanne)
. 2024 Jul;
11:1356323.
PMID: 39055695
Continuous medical and safety monitoring of subject data during a clinical trial is a critical part of evaluating the safety of trial participants and as such is governed by protocol...
2.
Meyvisch P, Ebrahimpoor M
Pharm Stat
. 2024 Feb;
23(4):530-539.
PMID: 38356204
Drug-drug interaction (DDI) trials are an important part of drug development as they provide evidence on the benefits and risks when two or more drugs are taken concomitantly. Sample size...
3.
Van der Elst W, Abad A, Coppenolle H, Meyvisch P, Molenberghs G
Pharm Stat
. 2021 May;
20(6):1216-1231.
PMID: 34018666
In the meta-analytic surrogate evaluation framework, the trial-level coefficient of determination quantifies the strength of the association between the expected causal treatment effects on the surrogate (S) and the true...
4.
Meyvisch P, Alonso A, Van der Elst W, Molenberghs G
Stat Med
. 2020 Sep;
39(26):3867-3878.
PMID: 32875590
The relationship between association and surrogacy has been the focus of much debate in the surrogate marker literature. Recently, the individual causal association (ICA) has been introduced as a metric...
5.
Santermans E, Ford P, Kreuter M, Verbruggen N, Meyvisch P, Wuyts W, et al.
Adv Ther
. 2019 Oct;
36(11):3059-3070.
PMID: 31565781
Introduction: Forced vital capacity is the only registrational endpoint in idiopathic pulmonary fibrosis clinical trials. As most new treatments will be administered on top of standard of care, estimating treatment...
6.
Alonso A, Meyvisch P, Van der Elst W, Molenberghs G, Verbeke G
J Biopharm Stat
. 2019 Jan;
29(3):468-477.
PMID: 30686082
Surrogate endpoints need to be statistically evaluated before they can be used as substitutes of true endpoints in clinical studies. However, even though several evaluation methods have been introduced over...
7.
Meyvisch P, Alonso A, Van der Elst W, Molenberghs G
Pharm Stat
. 2018 Dec;
18(3):304-315.
PMID: 30575256
The individual causal association (ICA) has recently been introduced as a metric of surrogacy in a causal-inference framework. The ICA is defined on the unit interval and quantifies the association...
8.
Meyvisch P, Kambili C, Andries K, Lounis N, Theeuwes M, Dannemann B, et al.
PLoS One
. 2018 Jul;
13(7):e0200539.
PMID: 30024924
The emergence of multidrug resistant-tuberculosis (MDR-TB), defined as Mycobacterium tuberculosis strains with in vitro resistance to at least isoniazid and rifampicin, has necessitated evaluation and validation of appropriate surrogate endpoints...
9.
Diacon A, van Brakel E, Lounis N, Meyvisch P, Van Baelen B, De Marez T, et al.
Am J Respir Crit Care Med
. 2017 Apr;
196(12):1612-1615.
PMID: 28448721
No abstract available.
10.
Alonso A, Van der Elst W, Meyvisch P
Stat Med
. 2016 Dec;
36(7):1083-1098.
PMID: 27966231
Several methods have been developed for the evaluation of surrogate endpoints within the causal-inference and meta-analytic paradigms. In both paradigms, much effort has been made to assess the capacity of...